Alexion Pharmaceuticals (NASDAQ:ALXN) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $10.25-10.40 for the period, compared to the Thomson Reuters consensus estimate of $9.93. The company issued revenue guidance of $4.86-4.89 billion, compared to the consensus revenue estimate of $4.84 billion.Alexion Pharmaceuticals also updated its FY 2019 guidance to $10.25-10.40 EPS.
Several equities research analysts have recently commented on the stock. BMO Capital Markets assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 12th. They issued an outperform rating and a $149.00 price target for the company. ValuEngine raised shares of Alexion Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, October 2nd. Cowen reaffirmed a buy rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Wednesday, October 16th. Piper Jaffray Companies set a $180.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a buy rating in a research report on Friday, September 6th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Alexion Pharmaceuticals in a research report on Wednesday, July 31st. They issued an overweight rating and a $172.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $159.76.
NASDAQ ALXN traded down $0.99 on Thursday, hitting $105.64. 76,908 shares of the company’s stock traded hands, compared to its average volume of 1,689,730. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86. The firm’s 50-day moving average price is $101.73 and its two-hundred day moving average price is $117.93. The firm has a market capitalization of $22.26 billion, a PE ratio of 14.87, a P/E/G ratio of 0.97 and a beta of 1.67.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.